Bryan O’Donnell, Head of Quality at Gaelic Laboratories, explains how to navigate GMP challenges to ensure your company ...

Continuous manufacturing (CM) has become a contentious topic in the modern pharmaceutical lexicon, driven by divergent ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

Viracta Therapeutics, Inc., a clinical-stage precision oncology company dedicated to treating and preventing virus-associated ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.

Taste-masking technologies, such as coatings, flavoring agents and complexation, play a key role in transforming unpalatable active ingredients into more agreeable forms. Additionally, optimizing ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

4Q Earnings: $3.7 billion (loss of $1.2 billion 4Q23) FY Earnings: $17.1 billion (earnings were $365 million FY23) ...